// App-Quantinova.ai

4573 : Dynamic changes of the immune infiltrate after neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).

Researchers

Presenter

  • Axel Bex

Principal Investigators

  • Yasmin Abu-Ghanem

  • Johannes V. Van Thienen

  • Niels Graafland

  • Brunolf Lagerveld

  • Patricia Zondervan

  • Harrie Beerlage

  • Jeroen van Moorselaar

  • Mark Kockx

  • Pieter-Jan Van Dam

  • Bernadett Szabados

  • Christian U. Blank

  • Thomas Powles

  • John B. A. G. Haanen

Medical Centers

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Onze Lieve Vrouwe Gasthuis, Amsterdam, Noord-Holland, Netherlands

  • VU University Medical Center, Amsterdam, Netherlands

  • CellCarta, Wilrijk, Belgium

  • Bart's Cancer Institute, London, United Kingdom

  • Department of Pathology, the Netherlands Cancer Institute, Amsterdam, Netherlands

  • Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust,, London, United Kingdom

Locations

  • Netherlands

  • Israel

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

Biomarkers

  • Programmed death-ligand 1

  • Granzyme B

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Inlyta

  • Avelumab

  • SP263

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • II

Study Id's

  • NCT03341845

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved